A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2002
12/19/2002	DE10128331A1 New 2-(heteroarylsulfonyl-amino)-benzamide derivatives, which are potassium ion channel blocking antiarrhythmic agents, useful for e.g. treating atrial fibrillation or flutter
12/19/2002	DE10127897A1 Combined pharmaceutical formulation for treating osteoporosis or related disorders, comprising core of dried plant extract enclosed in sheath of calcium salt
12/19/2002	DE10127712A1 Use of immunoglobulin M for treatment and prevention of systemic lupus erythematosus, administered subcutaneously or intramuscularly
12/19/2002	DE10121003A1 Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen Anthranilic acid amides, processes for preparing, their use as a medicament as well as pharmaceutical compositions containing them
12/19/2002	CA2487039A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2487038A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2451117A1 Facially amphiphilic polymers as anti-infective agents
12/19/2002	CA2450720A1 In vivo bioreactors
12/19/2002	CA2450628A1 Benzothiophene compounds having antiinfective activity
12/19/2002	CA2450625A1 Isoquinoline compounds having antiinfective activity
12/19/2002	CA2450617A1 Methyl analogs of simvastatin as novel hmg-coa reductase inhibitors
12/19/2002	CA2450557A1 Substituted aminoalcohols useful in treatment of alzheimer's disease
12/19/2002	CA2450400A1 Medicinal compositions
12/19/2002	CA2450384A1 Process for the production of zaleplon
12/19/2002	CA2450379A1 Molecular signatures of commonly fatal carcinomas
12/19/2002	CA2450366A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
12/19/2002	CA2450316A1 Cd10-activated prodrug compounds
12/19/2002	CA2450315A1 Dopamine receptor ligands and therapeutic methods based thereon
12/19/2002	CA2450285A1 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	CA2450271A1 Novel phenylalkyl diamine and amide analogs
12/19/2002	CA2450269A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450265A1 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
12/19/2002	CA2450262A1 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
12/19/2002	CA2450238A1 Oral pharmaceutical composition containing a statin derivative
12/19/2002	CA2450220A1 Cyclopentane heptan (ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
12/19/2002	CA2450205A1 Aminediols for the treatment of alzheimer's disease
12/19/2002	CA2450202A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002	CA2450167A1 Macrocycles useful in the treatment of alzheimer's disease
12/19/2002	CA2450113A1 Vanilloid receptor-related nucleic acids and polypeptides
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449987A1 Treatment of central neuropathic pain
12/19/2002	CA2449964A1 Crosslinkable macromers
12/19/2002	CA2449962A1 Use of glycosaminoglycans for the treatment of hiv-associated nephropathy
12/19/2002	CA2449957A1 Arylazo-substituted imidazole for the treatment of stress urinary incontinence
12/19/2002	CA2449948A1 Methods of treating alzheimer's disease
12/19/2002	CA2449944A1 Compositions comprising nitrofurantoin and uva ursi
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449673A1 Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449629A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002	CA2449571A1 Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
12/19/2002	CA2449544A1 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002	CA2449519A1 Controlled release dosage forms using acrylic polymer, and process for making the same
12/19/2002	CA2449517A1 Tissue-specific endothelial membrane proteins
12/19/2002	CA2449256A1 Modulators of peroxisome proliferator activated receptors
12/19/2002	CA2449249A1 Nr2b receptor antagonists for the treatment or prevention of migraines
12/19/2002	CA2449247A1 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002	CA2449213A1 Ophthalmic compositions comprising hyaluronic acid
12/19/2002	CA2449189A1 Naphtothiazine positive allosteric ampa receptor modulators (paarm)
12/19/2002	CA2448764A1 N-arylphenylacetamide derivatives and pharmaceutical compositions containing the same
12/19/2002	CA2448763A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
12/19/2002	CA2448552A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	CA2448543A1 Breath protection microcapsules
12/19/2002	CA2448518A1 New compounds useful in reflux disease
12/19/2002	CA2447687A1 Substituted 1-benzazepines and derivatives thereof
12/19/2002	CA2447557A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002	CA2446223A1 Stabilized dispersion of phytosterol in oil
12/19/2002	CA2445653A1 Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
12/19/2002	CA2445605A1 Treatment or prophylaxis of insulin-producing cell graft rejection
12/19/2002	CA2445471A1 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotic acetylcholine receptors
12/19/2002	CA2445467A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
12/18/2002	WO2001097784A1 Process for producing phospholipid-containing drugs
12/18/2002	EP1267171A1 Cofactor-based screening method for nuclear receptor modulators
12/18/2002	EP1266900A1 Carbamates of rapamycin
12/18/2002	EP1266899A2 Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266896A1 Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266888A1 Quinoline derivatives and medicinal use thereof
12/18/2002	EP1266887A2 Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them
12/18/2002	EP1266664A1 Preparations for chondrogenesis
12/18/2002	EP1266661A1 Anticancer compositions
12/18/2002	EP1266660A1 Heme oxygenase-1 inducers or induction enhancers
12/18/2002	EP1266659A1 Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
12/18/2002	EP1266658A2 Use of betulinic acid derivatives for the treatment and prevention of melanoma
12/18/2002	EP1266656A1 Anionic exchange polymer complexes of buspirone
12/18/2002	EP1266654A1 Stabilised amlodipine maleate formulations
12/18/2002	EP1266651A2 UV absorbing and photostabilizing agents and compositions and external preparation for skin
12/18/2002	EP1266578A1 Feed preparation for animals, especially for poultry
12/18/2002	EP1266224A1 Modulation of histone deacetylase
12/18/2002	EP1266029A1 Diagnosis of a person's risk of developing alcoholism
12/18/2002	EP1266023A2 LIPOPOLYSACCHARIDES (LPS) EXTRACTED FROM i ESCHERICHIA COLI /i
12/18/2002	EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002	EP1266013A2 Heparinase iii and uses thereof
12/18/2002	EP1266003A2 Kcnb: a potassium channel protein
12/18/2002	EP1266002A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1265999A2 Human schizophrenia gene
12/18/2002	EP1265996A2 Identification of modulators of the interferon gamma signaling pathway and their use in restenosis treatment
12/18/2002	EP1265995A2 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
12/18/2002	EP1265989A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
12/18/2002	EP1265942A2 Use of poly(diallylamine) polymers
12/18/2002	EP1265930A1 Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects
12/18/2002	EP1265924A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1265922A2 Agonists and antagonists of the receptor gpr19 and their use in appetite control
12/18/2002	EP1265921A1 Charged compounds comprising a nucleic acid binding moiety and uses therefor
12/18/2002	EP1265920A2 Angiogenesis-associated proteins, and nucleic acids encoding the same
12/18/2002	EP1265917A2 Tlp peptides and dna sequences coding the same
12/18/2002	EP1265914A2 Wnt-1 related polypeptides, and nucleic acids encoding the same
12/18/2002	EP1265913A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
12/18/2002	EP1265911A2 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
12/18/2002	EP1265907A2 Novel aryl fructose-1,6-bisphosphatase inhibitors
12/18/2002	EP1265905A1 Il-8 receptor antagonists

1 ... 5616 5617 5618 5619 5620 5621 5622 5623 5624 5625 5626 5627 5628 5629 5630 5631 5632 5633 5634 5635 5636 ... 7860